Compare EU & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | IRWD |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.5M | 526.7M |
| IPO Year | 2011 | 2009 |
| Metric | EU | IRWD |
|---|---|---|
| Price | $1.89 | $3.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $4.94 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | $43,155,000.00 | ★ $298,276,000.00 |
| Revenue This Year | $210.21 | $57.95 |
| Revenue Next Year | $30.67 | $4.39 |
| P/E Ratio | ★ N/A | $26.00 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $1.01 | $0.55 |
| 52 Week High | $4.19 | $5.78 |
| Indicator | EU | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 53.58 |
| Support Level | $1.81 | $3.07 |
| Resistance Level | $2.17 | $3.92 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 58.02 | 73.77 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.